Study of tazbentetol for people with ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests an investigational drug called tazbentetol for people with ALS (amyotrophic lateral sclerosis), a disease that affects nerve cells controlling muscles. The goal is to see if it is safe and effective, and it may help slow the progression of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a diagnosis of ALS and meet the study's risk score criteria.
- You are on a stable dose of your current ALS treatment.
- You are willing to use contraception if applicable.
- You are able to give informed consent and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests whether repetitive TMS (transcranial magnetic stimulation) can help people with ALS. It uses a special type of TMS that is repeated and measured. You would lie comfortably for about an hour while receiving the treatment.
This trial tests whether an experimental drug called tideglusib can slow the progression of ALS. It is for people with a recent ALS diagnosis whose breathing is still fairly strong.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.
This study tests a new medicine called BIIB147 to see if it is safe and to learn how it affects people with ALS. It may help slow the progression of the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.